Clinical Trials
14
Active:5
Completed:7
Trial Phases
3 Phases
Phase 1:7
Phase 2:6
Phase 3:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (14 trials with phase data)• Click on a phase to view related trials
Phase 1
7 (50.0%)Phase 2
6 (42.9%)Phase 3
1 (7.1%)A Study to Evaluate the Pharmacokinetics Similarity of CBP-201 in Healthy Adult Chinese Subjects
Phase 1
Completed
- Conditions
- Healthy Adult Subjects
- First Posted Date
- 2023-06-26
- Last Posted Date
- 2023-10-31
- Lead Sponsor
- Suzhou Connect Biopharmaceuticals, Ltd.
- Target Recruit Count
- 324
- Registration Number
- NCT05917782
- Locations
- 🇨🇳
The Second Hospital of Anhui Medical University, Hefei, Anhui, China
A Study to Evaluate the Safety and Efficacy of CBP-201 in Chinese Adult Subjects With Moderate to Severe AD
- First Posted Date
- 2023-06-15
- Last Posted Date
- 2023-12-11
- Lead Sponsor
- Suzhou Connect Biopharmaceuticals, Ltd.
- Target Recruit Count
- 360
- Registration Number
- NCT05905133
- Locations
- 🇨🇳
Connect Investigative Site 01, Beijing, Beijing, China
🇨🇳Connect Investigative Site 41, Beijing, Beijing, China
🇨🇳Connect Investigative Site 14, Fuzhou, Fujian, China
CBP-201 in Adolescent and Adult Patients With Moderate-to-severe Atopic Dermatitis
- First Posted Date
- 2022-11-14
- Last Posted Date
- 2023-03-21
- Lead Sponsor
- Suzhou Connect Biopharmaceuticals, Ltd.
- Registration Number
- NCT05614817
A Study On Human Mass Balance And Biotransformation
- First Posted Date
- 2021-09-10
- Last Posted Date
- 2022-04-05
- Lead Sponsor
- Suzhou Connect Biopharmaceuticals, Ltd.
- Target Recruit Count
- 6
- Registration Number
- NCT05040113
- Locations
- 🇨🇳
Connect Investigative Site, Suzhou, Jiangsu, China
A Study to Evaluate the Efficacy and Safety of CBP-201 in Moderate to Severe Atopic Dermatitis in China
Phase 2
Completed
- Conditions
- Moderate-to-severe Atopic Dermatitis
- Interventions
- Drug: Placebo
- First Posted Date
- 2021-08-23
- Last Posted Date
- 2024-05-01
- Lead Sponsor
- Suzhou Connect Biopharmaceuticals, Ltd.
- Target Recruit Count
- 330
- Registration Number
- NCT05017480
- Locations
- 🇨🇳
Connect Investigative Site 33, Hefei, Anhui, China
🇨🇳Connect Investigative Site 01, Beijing, Beijing, China
🇨🇳Connect Investigative Site 02, Beijing, Beijing, China
- Prev
- 1
- 2
- Next
News
No news found